Probatebeta
Target

MAP2K2

Dual specificity mitogen-activated protein kinase kinase 2

As of the edition of 20 October 2026, MAP2K2 (dual specificity mitogen-activated protein kinase kinase 2, UniProt P36507) has 14 drugs tested at it and 17 companies on the list, 6 on route A and 5 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
P36507
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
In more than one place
Solved structures
3
Disease areas
Cancer; Skin and connective tissue; Digestive system; Lungs and airways; Nervous system; Hormones; Blood and lymph; Inherited and neonatal
Registered trials of its drugs
593

Drugs at this target

StatusCount
Marketed4
Active2
Went quiet3
Stopped5
Total14
DrugStatusFurthest phaseUS protection
TrametinibMarketedPhase 4Ends 2030
BinimetinibMarketedPhase 4Ends 2033
SelumetinibMarketedPhase 3Ends 2032
AvutometinibMarketedPhase 3Ends 2032
TunlametinibActivePhase 4none listed
LuvometinibActivePhase 3none listed
RefametinibWent quietPhase 2none listed
NedometinibStoppedPhase 2none listed
CI-1040Went quietPhase 2none listed
WX-554StoppedPhase 2none listed
ZapnometinibStoppedPhase 2none listed
AS-703988StoppedPhase 1none listed

12 of 14 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A6
Route B5
Engaged5
Undetermined1
Total on the list17
Three companies on route A or B, with the route only
CompanyRoute
NovartisRoute B
PfizerRoute B
AstraZenecaRoute B

The other 14 companies at MAP2K2

In the product

17 companies in all; 14 are not named here, and no score is.

See the 17 companies at MAP2K2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

Other targets in cancer

Companies holding approvals at MAP2K2